Join your peers at the only conference dedicated to the leading causes of mortality and morbidity in diabetes, this autumn, in London. Our distinguished faculty unite the fields of pharmacology, nanotechnology and clinical medicine to target atherosclerosis, endothelial inflammation and end-stage renal disease.
SMi's unique program brings together the latest research from those at the forefront of attenuating the complications arising from hyperglycaemia, dyslipidaemia, and angiopathy.
“This conference is an excellent one stop shop to up-skill on current issues in diabetes therapy. I’m happy to chair what will no doubt be a very stimulating session.” – Phil Ambery, Medical Director, GlaxoSmithKline
Key Reasons to Attend:
Receive clinical updates on novel GLP1 receptor agonists, and SLGT2 and DPP-4 inhibitors
Utilise biomarkers and imaging for the development of novel therapies for diabetes
Discuss new therapeutic targets to reduce hypertension, hyperkalaemia and endothelial inflammation in diabetes
Remain abreast of new EU and FDA guidelines on clinical trials on risk-benefit assessment
Capitalise on the effects of targeting RAAS, CCN2 and CCN3 inhibitors
Review clinical results from the DEMAND study
Key Speakers Include:
James F. List, Vice President and Full Development Lead, Dapagliflozin, Bristol-Myers Squibb
John Wilding, Professor of Medicine & Honorary Consultant Physician, Head of Department of Obesity and Endocrinology, University of Liverpool Hospital
Martin Siman, Director, Design and Interpretation Centre of Excellence, AstraZeneca
Philip Ambery, Director, Clinical Development, GlaxoSmithKline
Sandra Souza, Team Lead, Molecular Biomarkers, PPDM , Merck Sharp & Dohme
Diabetes: Secondary Complications, Regulation and Innovation, promises to be a unique platform for networking, problem solving and learning from timely case studies. This really is a unique event not to be missed.
Book online at www.smi-online.co.uk/goto/2013diabetes-conference20.asp